Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer

被引:257
作者
Cedres, S. [1 ,2 ]
Torrejon, D. [1 ]
Martinez, A. [1 ,2 ]
Martinez, P. [1 ,2 ]
Navarro, A. [1 ]
Zamora, E. [1 ]
Mulet-Margalef, N. [1 ]
Felip, E. [1 ]
机构
[1] Vall dHebron Univ Hosp, Med Oncol Serv, Barcelona, Spain
[2] Univ Autonoma Barcelona, E-08193 Barcelona, Spain
关键词
Non-small cell lung cancer (NSCLC); Neutrophil to lymphocyte ratio; Prognostic factor; Inflammation; PREDICTS SURVIVAL; SYSTEMIC INFLAMMATION; COMPLETE RESECTION;
D O I
10.1007/s12094-012-0872-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neutrophil to lymphocyte ratio (NLR), an index of systemic inflammation, has been associated with worse survival for many types of cancer. The aim of this study is to investigate the clinical significance of the blood NLR as a prognostic factor in non-small cell lung cancer (NSCLC) patients. Stage IV NSCLC patients diagnosed in our institution between April 2004 and March 2009 were retrospectively reviewed. Potential prognostic factors such as histology, gender, performance status, response to chemotherapy and NLR were analyzed. NLR was assessed baseline and during chemotherapy treatment. Overall survival (OS) and progression free survival (PFS) were calculated by the Kaplan-Meier method. A total of 171 patients were included in the study and 60 patients (35.1 %) presented a NLR a parts per thousand yen5. Median survival for the entire cohort was 9.3 months. We found that patients with undifferentiated carcinoma and patients with NLR a parts per thousand yen5 had a worse survival. Median PFS of patients with NLR < 5 was 5.62 months and in patients with NLR a parts per thousand yen5 was 3.25 months (p = 0.098), and OS was 11.1 versus 5.6 months for patients with NLR < 5 and NLR a parts per thousand yen5, respectively (p = 0.017). During the chemotherapy treatment, patients who normalized NLR after one cycle presented better outcomes (OS 8.7 vs. 4.3 months, p = 0.001, for patients who normalized NLR and for patients who remained persistently elevated). After multivariate analysis, histology and NLR remained independent predictors of survival (p < 0.05). In our analysis, elevated NLR is a predictor of shorter survival in patients with advanced NSCLC and the variation of NLR during the first cycle of treatment predicts survival. NLR is an easily measured, reproducible test that could be considered to be incorporated in the routine practice in NSCLC patients.
引用
收藏
页码:864 / 869
页数:6
相关论文
共 21 条
[1]   Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer [J].
An, Xin ;
Ding, Pei-Rong ;
Li, Yu-Hong ;
Wang, Feng-Hua ;
Shi, Yan-Xia ;
Wang, Zhi-Qiang ;
He, You-Jian ;
Xu, Rui-Hua ;
Jiang, Wen-Qi .
BIOMARKERS, 2010, 15 (06) :516-522
[2]   Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment [J].
Cho, HanByoul ;
Hur, Hye Won ;
Kim, Sang Wun ;
Kim, Sung Hoon ;
Kim, Jae Hoon ;
Kim, Young Tae ;
Lee, Kook .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (01) :15-23
[3]   Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma [J].
Gomez, Dhanwant ;
Morris-Stiff, Gareth ;
Toogood, Giles J. ;
Lodge, J. Peter A. ;
Prasad, K. Rajendra .
JOURNAL OF SURGICAL ONCOLOGY, 2008, 97 (06) :513-518
[4]  
Greene F., 2002, AJCC cancer staging handbook: From the AJCC cancer staging manual, V6th
[5]   The IASLC lung cancer staging project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours [J].
Groome, Patti A. ;
Bolejack, Vanessa ;
Crowley, John J. ;
Kennedy, Catherine ;
Krasnik, Mark ;
Sobin, Leslie H. ;
Goldstraw, Peter .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :694-705
[6]   Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases [J].
Halazun, K. J. ;
Aldoori, A. ;
Malik, H. Z. ;
Al-Mukhtar, A. ;
Prasad, K. R. ;
Toogood, G. J. ;
Lodge, J. P. A. .
EJSO, 2008, 34 (01) :55-60
[7]   Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data [J].
Hoang, T ;
Xu, RH ;
Schiller, JH ;
Bonomi, P ;
Johnson, DH .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) :175-183
[8]  
Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21387]
[9]   High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy [J].
Kao, Steven C. H. ;
Pavlakis, Nick ;
Harvie, Rozelle ;
Vardy, Janette L. ;
Boyer, Michael J. ;
van Zandwijk, Nico ;
Clarke, Stephen J. .
CLINICAL CANCER RESEARCH, 2010, 16 (23) :5805-5813
[10]   The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma [J].
Keizman, Daniel ;
Ish-Shalom, Maya ;
Huang, Peng ;
Eisenberger, Mario A. ;
Pili, Roberto ;
Hammers, Hans ;
Carducci, Michael A. .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) :202-208